SignaBlok selected as a RESI Pitch Challenge finalist to pitch on company’s oncology program at the 2019 Redefining Early Stage Investments (RESI) Conference

SignaBlok presented data on preclinical antitumor activity of a first-in-class TREM-1 inhibitory peptide GF9 as monotherapy and in combo with chemotherapy or radiation at the 2019 AACR Annual Meeting

SignaBlok presented preclinical data supporting efficacy of ligand-independent TREM-1 inhibitor in ameliorating alcoholic liver disease at the Liver Meeting 2018: American Association for the Study of Liver Diseases (AASLD)

SignaBlok presented its concept of nature-inspired rational design of macrophage-targeted imaging and drug delivery system for detection and treatment of inflammation at the 2018 World Molecular Imaging Congress

SignaBlok awarded NIGMS / NIH SBIR Phase I grant to test novel TREM-1 therapy for treatment of sepsis

SignaBlok awarded NEI / NIH SBIR Phase I grant to test new approach to prevention and treatment of neovascular retinal diseases

SignaBlok awarded NCI / NIH SBIR Phase I grant to test first-in-class TREM-1 inhibitor in combination with chemotherapy for treatment of pancreatic cancer

SignaBlok presented preclinical data on efficacy of ultra high sensitivity MRI contrast agent for diagnostic imaging of atherosclerosis in a non-rodent animal model at the 2017 World Molecular Imaging Congress

SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for retinopathy of prematurity at the 2017 ARVO Annual Meeting

SignaBlok presented preclinical data on further development of a novel ligand-independent inhibitor of TREM-1 for treatment of lung and pancreatic cancer at the 2017 AACR Annual Meeting